| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (NCT03851081) | Roswell Park Cancer Institute | 2021-01-21 |
| Blinatumomab Bridging Therapy for BALL (NCT04556084) | Michael Burke | 2021-01-01 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105) | City of Hope Medical Center | 2020-11-18 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia (NCT04723901) | Shenzhen University General Hospital | 2020-10-20 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03991884) | University of Washington | 2019-09-24 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038) | M.D. Anderson Cancer Center | 2019-05-15 |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (NCT03739814) | National Cancer Institute (NCI) | 2019-05-08 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (NCT03808610) | M.D. Anderson Cancer Center | 2019-04-03 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03698552) | M.D. Anderson Cancer Center | 2018-08-24 |
| Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (NCT03504644) | ECOG-ACRIN Cancer Research Group | 2018-08-13 |
| Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (NCT03472573) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-05-09 |
| Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT03518112) | M.D. Anderson Cancer Center | 2018-04-18 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971) | Fred Hutchinson Cancer Center | 2017-11-03 |
| Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (NCT02879695) | National Cancer Institute (NCI) | 2017-10-25 |
| Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia (NCT04094766) | Second Affiliated Hospital of Xi'an Jiaotong University | 2017-08-01 |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (NCT02981628) | Children's Oncology Group | 2017-06-19 |
| Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (NCT02420717) | M.D. Anderson Cancer Center | 2015-07-15 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (NCT01371630) | M.D. Anderson Cancer Center | 2011-08-26 |